Who are Intravenous Diltiazem's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levamlodipine besylate, Amlodipine+Benazepril, Felodipine add Irbesartan, Eplerenone vs Amlodipine, nicardipine intravenous, Amlodipine 5 or 10 mg(oral).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-diltiazem.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Intravenous Diltiazem — Competitive Intelligence Brief

Intravenous Diltiazem (Intravenous Diltiazem) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-dihydropyridine calcium channel blocker. Area: Cardiovascular.

phase 3 Non-dihydropyridine calcium channel blocker L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous Diltiazem (Intravenous Diltiazem) — Oman Medical Speciality Board. Diltiazem is a non-dihydropyridine calcium channel blocker that inhibits calcium influx into cardiac and vascular smooth muscle cells, reducing heart rate and blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intravenous Diltiazem TARGET	Intravenous Diltiazem	Oman Medical Speciality Board	phase 3	Non-dihydropyridine calcium channel blocker	L-type voltage-gated calcium channel
Levamlodipine besylate	Levamlodipine besylate	Jiangsu Simcere Pharmaceutical Co., Ltd.	marketed	Dihydropyridine calcium channel blocker	L-type voltage-gated calcium channel
Amlodipine+Benazepril	Amlodipine+Benazepril	TSH Biopharm Corporation Limited	marketed	Calcium channel blocker + ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Felodipine add Irbesartan	Felodipine add Irbesartan	LanZhou University	marketed	Calcium channel blocker + Angiotensin II receptor blocker combination	L-type voltage-gated calcium channels; AT1 angiotensin II receptor
Eplerenone vs Amlodipine	Eplerenone vs Amlodipine	Brigham and Women's Hospital	marketed	Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine)	Mineralocorticoid receptor (eplerenone); L-type voltage-gated calcium channel (amlodipine)
nicardipine intravenous	nicardipine intravenous	Haseki Training and Research Hospital	marketed	Dihydropyridine calcium channel blocker	L-type voltage-gated calcium channel
Amlodipine 5 or 10 mg(oral)	Amlodipine 5 or 10 mg(oral)	GlaxoSmithKline	marketed	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-dihydropyridine calcium channel blocker class)

Oman Medical Speciality Board · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
Virginia Commonwealth University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous Diltiazem — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-diltiazem. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab